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Significant statement 
The U.S. Food and Drug Administration recently granted tissue-agnostic approval for the 
first-in-class TRK inhibitor larotrectinib for patients whose tumors harbor fusions in 
neurotrophic receptor tyrosine kinases (NTRKs).  These fusion genes have a frequency of 
less than 1% in unselected colorectal cancer patients. Using a multi-omics approach and a 
clinically annotated cohort of CRC patients, Cocco and colleagues showed that patients with 
sporadic, RAS/BRAF wild-type, mismatch repair deficient CRC tumors with MLH1 promoter 
methylation present fusions in kinase genes in 42% of cases,   and suggested a diagnostic 
framework to improve the selection of patients eligible for gene fusion testing.    
Commentary 
Genomic instability represents a key hallmark of cancer. Indeed, the presence of 
microsatellite or chromosomal instability underpins cancer initiation and progression in many 
tumor types, including colorectal cancer (CRC) (1).  In tumors with microsatellite instability 
(MSI), the presence of errors in short stretches of repeated nucleotides (microsatellites) is an 
epiphenomenon of defects in DNA mismatch repair (MMR) machinery genes (2).  On the 
other hand, chromosomal rearrangements can lead to balanced or unbalanced structural 
changes in coding and non-coding areas of the genome, resulting in gene fusions that often 
act as oncogenic drivers (3).  MSI occurs in approximately 2-3% of all cancers and 
approximately 3-5% of metastatic CRC (2).  Gene fusions appear to be involved in about 
16% of all cancers types, but targetable fusions involving kinases only occur in a minority of 
unselected CRC cases (3). 
Recently, the U.S. Food and Drug Administration (FDA) granted two tissue-agnostic 
accelerated approvals for anti-cancer agents based on their remarkable clinical activity 
irrespective of tumor type: the PD-1 inhibitor pembrolizumab was  granted extended 
approval to all patients with metastatic MSI-High (MSI-H) tumors in 2017; and the first-in-
class TRK inhibitor larotrectinib was recently approved for patients whose tumors harbor 
fusions in neurotrophic receptor tyrosine kinase (NTRK) 1, 2 or 3 (4).  Based on these 
ground-breaking findings, other tissue-agnostic drugs are currently in the pipeline; however, 
several hurdles remain.  First, the frequency of some of these genomic abnormalities is 
relatively low in the general cancer population, thus the identification of potentially 
responsive patients through rapid and cost-effective diagnostic tests is a major challenge.  
Second, there is a cultural barrier between genomic-driven tissue-agnostic cancer medicine 
and the disease-oriented approach of oncologists.  Even though the implementation of tumor 
molecular profiling boards in many institutions worldwide has contributed to improve patients’ 
access to international basket trials, the identification of specific groups of patients who are 
most likely to benefit from tissue-agnostic drugs remains an unmet need.     
In the current issue of Cancer Research, Cocco and colleagues characterized kinase fusions 
in patients with advanced CRC who underwent the MSK-IMPACT molecular testing at 
Memorial Sloan Kettering Cancer Center (MSKCC) over a period of approximately four years 
(5).  Tumors were tested for MSI, RAS/BRAF mutations, MLH1 promoter methylation 
(MLH1p). Gene fusions were assayed and/or validated using a custom RNA-seq panel; a 
subset of cases also underwent genome-wide methylation profiling using the Illumina 
MethylationEPIC platform.  
Overall, kinase gene fusions were identified in 0.9% of the 2314 CRC cases, confirming the 
low frequency of these genomic aberrations in an unselected CRC population.  However, 
when multi-omics data were combined and gene fusions were put in context of other 
molecular features, the authors observed that the frequency of fusions was significantly 
higher in the MSI-H population (5%) compared to the microsatellite stable (MSS) group 
(0.4%; p<0.001).  Fusions appeared more frequent in sporadic MMR-deficient MSI-H tumors 
with MLH1p and RAS/BRAF wild-type genotype (5).  Based on these findings, the authors 
proposed a diagnostic flow-chart that would help to rationalise molecular testing for gene 
fusions in CRC (5).  Indeed, the combined use of MSI and RAS/BRAF testing that is  already 
routinely used in clinical practice, along with the determination of MLH1 promoter 
methylation status, might help to narrow down the number of CRC patients to be tested for 
gene fusions resulting in a more sustainable and cost/effective approach.  Despite a few 
limitations related to the relatively small cohort and the fact that none of the patients with 
kinase fusions were in fact treated with driver-specific tyrosine kinase inhibitors, the study 
undoubtedly offers a new angle for the implementation of precision oncology in routine 
clinical practice.    
In line with the data reported by Cocco and colleagues (5), Sato and colleagues analyzed 
nearly 3000 CRC cases from Japan and described remarkably similar results, with tumors 
harboring fusions in kinase genes being enriched in sporadic MSI-H, MLH1p, RAS/BRAF 
wild-type CRC cases (6):  55% of sporadic CRC patients with MMR deficiency, MLH1p, and 
lack of mutations in the RAS/BRAF pathway harbored fusions genes.  When analysing MSS 
cases, the two cohorts showed almost identical frequency in fusion genes (0.4% in the 
MSKCC vs 0.5% in the Japanese cohort) (5,6).   
Consistent with these data, previous reports (7) have suggested an association between 
fusions in targetable kinase genes and MSI-H and RAS/BRAF wild-type status, and also 
highlighted a potential correlation between fusion genes and sidedness, thus providing one 
more clinical variable for the decisional algorithm.   Cocco and colleagues reported that 
approximately 70% of patients with gene fusions had proximal (i.e. right sided) primary 
cancers (5), and these data seem to align well with those presented by Pietrantonio and 
colleagues who reported 80% of patients with fusions being right sided (7).  These 
correlations between occurrence of fusion genes and sidedness are based on small 
numbers, thus require further validation before final conclusions can be drawn; however, if 
confirmed, they may offer a further clinical parameter to be incorporated in the decisional 
tree for the selection of patients’ eligibility for gene fusion testing.  Furthermore, any 
association between right sided tumors and increased frequency in fusions involving kinases 
might explain some of the cases of inherent resistance to epidermal growth factor receptor 
(EGFR) monoclonal antibodies in RAS/BRAF wild-type right sided primary CRC and offer 
potential therapeutic options for this subset of CRC patients.  Compared to the study by 
Pietrantonio and colleagues (7), the lack of detailed information on patient outcomes in the 
MSKCC study (5) precluded any analysis on the prognostic role of gene fusions among MSI-
H patients.  However, it is intriguing to believe that gene fusions might contribute to the poor 
prognosis of metastatic BRAF wild-type MSI-H CRCs as this may justify the lack of 
significance in the interaction test between MSI-H status and BRAF mutations in the pooled 
analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies (8).  
BRAF V600E mutations have been linked to the acquisition of the GpG Island Methylator 
phenotype (CIMP) in sporadic MSI-H CRC.  Indeed, upon activation of the BRAF/MEK/ERK 
signalling pathway, the transcriptional repressor MAFG is phosphorylated, and along with 
corepressor partner proteins such as BACH1, CHD8, and the DNA methyltransferase 
DNMT3B, binds to the MLH1 promoter and other CIMP genes causing hyper-methylation 
and transcriptional silencing (9).  Given the mutual exclusivity between fusions in kinase 
genes and activating BRAF mutations reported in the current and other similar studies (5-7), 
Cocco and colleagues (5) hypothesized that fusion genes might be responsible for inducing 
the CIMP phenotype in BRAF wild-type CRC; however, given that different onco-proteins 
might trigger the assembly of distinct repressor complexes on common promoters (9), this 
hypothesis will require further experimental validation using pre-clinical models. 
Although few cell lines and patient-derived xenografts from CRC patients with kinase genes 
fusions are already available, these fall short in capturing inter- and intra-patient 
heterogeneity.  From this prospective, refining the selection criteria for testing kinase gene 
fusions might translate into a more accurate selection of patients for molecular screening, 
thus enabling bio-banking efforts of patient-based models such as organoids (10) mimicking 
uncommon genetic drivers.  These models might prove critical for forward and reverse 
translation in order to understand molecular mechanisms and overcome primary or acquired 
resistance.   
Whether the diagnostic framework proposed by Cocco and colleagues could be extrapolated 
to other cancer types remains to be seen.  Nonetheless, this study highlights the paramount 
importance of integrating multi-omics data with detailed clinical annotation in defining niches 
of patients with targetable driver genes and, as such, likely to benefit from precision 
medicine approaches.  Although tissue-agnostic treatments are based on mechanisms of 
action rather than tissue specificity (4), an in-depth understanding of the molecular portraits 
of different tumor types is pivotal to identify sub-groups of patients enriched for certain 
genomic drivers, thus allowing resource prioritization and timely and cost/effective delivery of 
genomic characterization in the clinic.   
The results reported by Cocco and colleagues (5) widen the therapeutic horizon for some 
RAS/BRAF wild-type MSI-H colorectal cancers as these patients may benefit from both 
FDA-approved tissue-agnostic treatments.  However, it is worth mentioning that these 
patients represent a relatively small proportion of all metastatic CRC, and future efforts 
should continue to investigate better ways to identify fusion genes in MSS patients.  
Approximately one in two hundred MSS CRC patients harbors targetable gene fusions (5-7), 
and 97% of metastatic CRC cases are in fact microsatellite stable (2).  When these numbers 
are looked in the context of incidence of new metastatic CRC cases per year, they unveil the 
presence of a significant proportion of CRC patients that might gain a clear benefit from 
targeted therapies with kinase inhibitors and, as such, cannot be neglected.    
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